# Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

> **NCT07410234** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 110 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Toripalimab
- **RADIATION:** SBRT
- **DRUG:** standard neoadjuvant chemotherapy regimens

## Key facts

- **NCT ID:** NCT07410234
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-21
- **Primary completion:** 2028-02-21
- **Final completion:** 2029-02-21
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07410234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07410234, "Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07410234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*